Neurodevelopmental outcome of preterm infants enrolled in myo-inositol randomized controlled trial.
Ira Adams-ChapmanKristi L WatterbergTracy L NolenShawn HirschCarol A ColeC Michael CottenWilliam OhBrenda B PoindexterKristin M Zaterka-BaxterAbhik DasConra Backstrom LacyAnn Marie ScorsoneAndrea F DuncanSara B DeMauroRicki F GoldsteinTarah T ColaizyDeanne E Wilson-CostelloIsabell B PurdySusan R HintzRoy J HeyneGary J MyersJanell FullerStephanie MerharHeidi M HarmonMyriam Peralta-CarcelenHoward W KilbrideNathalie L MaitreBetty R VohrGirija NatarajanHelen Mintz-HittnerGraham E QuinnDavid K WallaceRichard J OlsonFaruk H OrgeIrena TsuiMichael GaynonAmy K HutchinsonYu-Guang HeTimothy W WinterMichael B YangKathryn M HaiderMartin S CogenDenise HugDon L BremerJohn P DonahueWilliam R LucasDale L PhelpsRosemary D Higginsnull nullPublished in: Journal of perinatology : official journal of the California Perinatal Association (2021)
Treatment group did not affect the risk of death or survival with moderate/severe NDI. Despite early termination, this study represents the largest RCT of extremely preterm infants treated with myo-inositol with neurodevelopmental outcome data.